ArticleBlood and lymphatic cancer : targets and therapy2026
Study on the Role of Neutrophil Extracellular Traps-Based Risk Model and Discriminative Gene LTF in the Prognosis of Acute Myeloid Leukemia and the Regulation of Immune Microenvironment.
Article in Blood and lymphatic cancer : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dysregulation of neutrophil extracellular traps (NETs) formation is implicated in cancer progression, coagulation, and metastasis; however, the association with acute myeloid leukemia (AML) prognosis and the immune microenvironment remains poorly understood due to the inherent heterogeneity of NETs. This study aimed to elucidate the role of NETs-related genes in AML pathogenesis, risk stratification, and immune modulation. Methods: We employed comprehensive bioinformatics approaches to analyze NETs-related gene expression profiles from cBioPortal, UCSC Xena, and Gene Expression Omnibus (GEO) databases. A prognostic model was constructed using 16 NETs-related gene signatures, with rigorous validation performed in both internal and external cohorts. Multivariate Cox regression analyses assessed the model's independence as a prognostic indicator for overall survival (OS), and a clinical nomogram was developed for practical application. Additionally, immune cell infiltration and microenvironment characteristics were evaluated through enrichment analyses to correlate NETs activity with immunological features. Results: The NETs-based prognostic model demonstrated robust predictive value for OS in AML patients across validation cohorts and was identified as an independent prognostic factor via multivariate Cox regression. This model enhanced existing risk stratification systems, with high NETs scores significantly associated with neutrophil enrichment and an immunosuppressive tumor microenvironment. Lactotransferrin (LTF) emerged as a pivotal NETs-related gene: its overexpression correlated strongly with adverse prognosis, poor chemotherapy response, and extensive remodeling of the immune landscape, including heightened neutrophil infiltration and immunosuppressive signatures. Discussion: Our comprehensive analysis of NETs in AML suggests that NETs have a role in the tumor microenvironment and prognosis. LTF is a promising candidate biomarker of therapy response and prognostic prediction, which may contribute to individualized clinical decision-making. Further functional validation and prospective clinical studies are warranted to translate our observations into targeted interventions and refine risk-adapted treatment protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.